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In clinical epidemiology, the association between a risk fac-
tor and a disease can be flawed by bias and confounding. 
This should be prevented by a proper design and adjust-
ment. One important aspect is the reliability of exposure 
and outcome assessment to prevent misclassification bias. 
Elsewhere in this journal, Cote et al. [1] describe a study 
on the association between statin use and glioma, in which 
they employ statin use during interview as the risk factor 
of interest.
Everybody knows and understands that the strength of 
a bracelet is determined by the weakest chain. In many 
pharmaco-epidemiological studies with interview data in 
the past, exposure assessment was the weakest chain. Why 
would exposure be more easily misclassified than the out-
come in the study of Cote et al.? First of all, due to the fact 
that the validation of cases was performed by reference to 
the medical record, false-positive misclassification of the 
outcome is unlikely, even in the absence of brain pathology. 
False-negative misclassification is certainly possible but in 
the end, cases of glioma are probably detected sooner or 
later and the missing of early cases of such a rare disease 
in a population-based cohort study, is probably not much 
of a threat to the risk estimate as long as it is non-differen-
tial between users and non-users. However, misclassifica-
tion of exposure may be a different story. Already in 1977, 
Copeland et al. [2] demonstrated how devastating exposure, 
as well as outcome misclassification can be for risk esti-
mates. That a drug interview at baseline as a determinant 
for events during follow-up leads to exposure misclassifica-
tion is easily understood. First, because a study on adher-
ence to statins demonstrated that more than 50% of users 
stops within 2 years [3]. Second, because it is was shown 
that during a long follow-up period, many non-users of 
chronic medication according to an interview at baseline will 
become users because they are started during the years after 
the baseline interview [4]. Therefore, it is best practice to try 
to obtain filling data on medicines as such data on continu-
ous use can be analysed with the drug as a time-dependent 
variable with a lower chance of exposure misclassification 
[5]. However, several established population-based cohort 
studies do not have such information, and in most developed 
countries nowadays privacy legislation makes it difficult to 
link such studies to health care data from health mainte-
nance organizations and insurance companies. To investigate 
a duration-effect relationship, Cote et al. tried to circum-
vent this by using repetitive interview data. Duration of use 
was estimated by summing use across each 2-year period 
encompassed by the follow-up questionnaires and classified 
as never use, 0–4 years, ≥ 4–8 years, and > 8 years [1]. In 
how far this relates to real use during the whole period could 
not be verified.
The author of this Commentary decided to test this 
in the Rotterdam Study, a population-based prospec-
tive cohort study which started in 1990 and of which the 
details have been described earlier in this journal [6]. To 
this end, we investigated baseline statin use according to 
interview in the first two cohorts because the third cohort 
had less than 4 cycles. Therefore, we studied RSI-3 and 
RSII-1 during the period 1997–2001 (see Fig. 1), as well 
as during the subsequent 4 interview cycles that followed 
until the period 2014–2016. There were 7741 out of 7808 
study participants for whom we had a baseline interview 
during which 906 of them (11.7%) told that they were 
using statins (confirmed to the interviewers by showing the 
labelled boxes/canisters). Would this be taken as a proxy 
indicator of use during follow-up (as is done in many 
population-based studies with only a baseline medica-
tion interview), 129 users according to interview (14.2%) 
would not have been confirmed by filling data (Tables 1, 
2) while no less than 1502 participants classified as non-
user would have received statins later during follow-up. 
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This would mean that taking baseline use as an indica-
tor of any use during follow-up would catch only 34% of 
users according to pharmacy filling data. Comparing these 
results to any use during follow-up during the successive 
interviews with pharmacy dispensing data improves the 
concordance to 84% with only 16% being misclassified 
as non-users during interview. In Table 3, we show the 
average number of cumulative days of statin use accord-
ing to pharmacy filling data within the Rotterdam Study, 
stratified by the number of interviews during which par-
ticipants declared that they used statins. Would we take 
1 interview as a 2-year period of statin use—as done by 
Cote et al. because their interviews were biennual—the 
numbers are remarkably similar to full-time use during the 
corresponding calendar time but would lead to an overesti-
mation. However, in the Rotterdam Study interviews were 
taken every 4 years on average and between the 2nd and 
3rd interviews there was even a delay of 7 years (Fig. 1). 
Hence, assuming that statin use would continue between 
two subsequent interviews in which participants told that 
they used statins, would overestimate actual use. Although 
this suggests that pharmacy filling data are a better indica-
tor of actual use, it may be concluded that analyses with 
repetitive interviews certainly improve the true exposure 
Fig. 1  Rotterdam Study cohorts
Table 1  Users of statins according to interview at baseline and statin 
users according to pharmacy filling data during follow-up (absolute 
numbers and percentages of total)
Sensitivity 34.1%; specificity 97.6%; kappa 0.38
Use pharmacy Non-use phar-
macy
Total
Use interview 777 (10.0%) 129 (1.7%) 906 (11.7%)
Non-use inter-
view
1502 (19.4%) 5333 (68.9%) 6835 (88.3%)
Total 2279 (70.6%) 5462 (70.6%) 7741 (100%)
Table 2  Users of statins according to interview during 4 subsequent 
interviews and statin users according to pharmacy filling data during 
follow-up (absolute numbers and percentages of total)
Sensitivity 83.5%; specificity 93.5%; kappa 0.77
Use pharmacy Non-use phar-
macy
Total
Use interview 1903 (24.6%) 354 (4.6%) 2257 (29.2%)
Non-use inter-
view
376 (4.9%) 5108 (66.0%) 5484 (70.8%)
Total 2279 (29.4%) 5462 (70.6%) 7741 (100%)
Table 3  Cumulative number 
of days of use according 
to pharmacy filling data in 
comparison to the number 
of interviews with statin use, 
assuming continuous use during 






2-Year intervals (days) % 4-Year intervals %
1 727 (SE 24) 1–730 99.6 1–1460 49.8
2 1605 (SE 44) 731–1460 110.0 1461–2920 55.0
3 2488 (SE 85) 1461–2190 113.6 2921–4380 56.8
4 3027 (SE 125) 2191–2920 103.7 4381–5840 51.8
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estimates in comparison to studies where only baseline use 
is taken as indicator of statin use.   
Apparently, repeated interview data on drug use are a 
relatively good proxy indicator for continuous filling data 
from pharmacies and much better than using a single base-
line interview as exposure indicator in a population-base 
cohort study. Of course, there are a few important considera-
tions to take into account. First, a single example with data 
from the Rotterdam Study in which repeated interview data 
on statins are grossly similar to continuous pharmacy data 
does not prove that we would encounter an identical situ-
ation in the dataset of Cote et al. Even stronger, it tells us 
nothing about the association with glioma, a type of cancer 
which is too rare for a medium-sized population like the 
one in Rotterdam. Second, the availability of detailed and 
prospectively gathered information on type, daily dose, and 
duration on filled prescriptions facilitates subtle analyses 
which can never be made with 4 repeated interviews on use 
of medicines during a more than 8 years-period. But also, we 
should acknowledge that drug interviews have their strong 
points because it is probably a better indicator of adher-
ence to therapy and it facilitates information on the use of 
‘over-the-counter’ medicines and of medicines obtained 
during hospital admission which often fail in community 
pharmacy-derived filling data. Apparently, both interview 
and pharmacy filling data have their own advantages and 
limitations, and preferably both types of exposure estima-
tions are used complementary.
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